City-based MSN Group has announced free home delivery of ‘Faviflow’ for patients experiencing mild to moderate COVID-19 symptoms across 170 cities. The drug is available with leading pharmacies and hospitals. MSN is partnering with retail pharmacies to facilitate delivery for patients in need.

Priced at ₹33, Faviflow is the world’s most affordable Favipiravir produced by MSN Labs and is currently available in 200 mg dosage strength while the 400 mg drug will be introduced into the market soon to reduce the pill burden. “We want our product to be available to patients across the country,” said CMD M.S.N. Reddy.

Favipiravir has been granted approval by DCGI for treatment of suspected or lab-confirmed cases of COVID in adults and children, hospitalised with mild to moderate symptoms. Faviflow (Favipiravir) can be purchased by producing a prescription by a healthcare practitioner at the outlet, he said.

As part of the COVID-19 treatment range, MSN has already launched Oseltamivir 75 mg capsules another anti-viral medication under the brand name ‘Oselow’. One can call their helpline number (9100591030) or e-mail to, a press release said.

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Show Less Plan

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Faster pages

Move smoothly between articles as our pages load instantly.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.


A one-stop-shop for seeing the latest updates, and managing your preferences.

Personalised recommendations

A select list of articles that match your interests and tastes.


We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Source link


Please enter your comment!
Please enter your name here